Novel Biomarker of Collagen Degradation Can Identify Patients Affected With Both Axial Spondyloarthritis and Crohn Disease.
Signe Holm NielsenAndrew StahlyEmilie H RegnerAnne Christine Bay-JensenMorten Asser KarsdalKristine A KuhnPublished in: The Journal of rheumatology (2022)
Degradation of type IV collagen quantified by C4M showed a complete separation of patients with CD-axSpA overlap, compared to axSpA, CD, and HCs, and indicates excessive collagen degradation and epithelial turnover. This biomarker could potentially be used to identify patients affected by both manifestations and to guide treatment decisions.